El índice h5 es el índice h de los artículos publicados en los últimos 5 años completos. Se trata del número mayor h en cuanto a que h artículos publicados entre 2014 - 2018 deben tener al menos h citas cada uno.ocultar
La mediana h5 de una publicación es el número mediano de citas de los artículos que componen el índice h5.ocultar
Título / AutorCitado porAño
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
DA Arber, A Orazi, R Hasserjian, J Thiele, MJ Borowitz, MM Le Beau, ...
Blood 127 (20), 2391-2405
27752016
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
SH Swerdlow, E Campo, SA Pileri, NL Harris, H Stein, R Siebert, ...
Blood 127 (20), 2375-2390
24202016
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
H Döhner, E Estey, D Grimwade, S Amadori, FR Appelbaum, T Büchner, ...
Blood 129 (4), 424-447
9652017
A systematic analysis of global anemia burden from 1990 to 2010
NJ Kassebaum, R Jasrasaria, M Naghavi, SK Wulf, N Johns, R Lozano, ...
Blood 123 (5), 615-624
7712014
Current concepts in the diagnosis and management of cytokine release syndrome
DW Lee, R Gardner, DL Porter, CU Louis, N Ahmed, M Jensen, SA Grupp, ...
Blood 124 (2), 188-195
7072014
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
DP Steensma, R Bejar, S Jaiswal, RC Lindsley, MA Sekeres, ...
Blood 126 (1), 9-16
5862015
Antibody-modified T cells: CARs take the front seat for hematologic malignancies
MV Maus, SA Grupp, DL Porter, CH June
Blood 123 (17), 2625-2635
5662014
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib
JC Byrd, RR Furman, SE Coutre, JA Burger, KA Blum, M Coleman, ...
Blood 125 (16), 2497-2506
5422015
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia
JR Brown, JC Byrd, SE Coutre, DM Benson, IW Flinn, ...
Blood 123 (22), 3390-3397
4802014
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with> 30% blasts
H Dombret, JF Seymour, A Butrym, A Wierzbowska, D Selleslag, JH Jang, ...
Blood 126 (3), 291-299
4392015
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era
Z Zhou, LH Sehn, AW Rademaker, LI Gordon, AS LaCasce, ...
Blood 123 (6), 837-842
4322014
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes
E Rumi, D Pietra, V Ferretti, T Klampfl, AS Harutyunyan, JD Milosevic, ...
Blood 123 (10), 1544-1551
4202014
Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials
N van Es, M Coppens, S Schulman, S Middeldorp, HR Büller
Blood 124 (12), 1968-1975
3752014
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms
P Lundberg, A Karow, R Nienhold, R Looser, H Hao-Shen, I Nissen, ...
Blood 123 (14), 2220-2228
3632014
CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
SL Maude, DT Teachey, DL Porter, SA Grupp
Blood 125 (26), 4017-4023
3532015
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages
JF Emile, O Abla, S Fraitag, A Horne, J Haroche, J Donadieu, ...
Blood 127 (22), 2672-2681
3472016
GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity
MA Spinner, LA Sanchez, AP Hsu, PA Shaw, CS Zerbe, KR Calvo, ...
Blood 123 (6), 809-821
3322014
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial
K Fischer, J Bahlo, AM Fink, V Goede, CD Herling, P Cramer, ...
Blood 127 (2), 208-215
3302016
Thrombosis: tangled up in NETs
K Martinod, DD Wagner
Blood 123 (18), 2768-2776
3302014
Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry
J Beyer-Westendorf, K Förster, S Pannach, F Ebertz, V Gelbricht, ...
Blood 124 (6), 955-962
3272014
1 - 20
Las fechas y los recuentos de citas son estimados y se determinan de forma automática mediante un programa informático.